ClinicalTrials.gg
CompletedNCT01493557Updated Oct 5, 2015Results posted

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

A Phase 4 interventional study of pantoprazole and Pradaxa (dabigatran etexilate) in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 103 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-05.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,067
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.

Enrollment
4th of 35
1,067 · median 174
Started
2011
with 4 others
Phase 4
22 of 35
none open now
Registered
7th of 35
by date
Lead sponsor
7 of 35
Boehringer Ingelheim

Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 4th largest by enrollment, is one of 5 that started in 2011, is one of 22 in phase 4, and was the 7th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing dabigatran in Atrial Fibrillation as a file.
02

Study summary

This is a prospective and open label study that aims to enroll approximately 1200 patients with non-valvular atrial fibrillation (NVAF) not previously treated with Pradaxa® and free of gastrointestinal symptoms (GIS) for at least 2 weeks prior to enrolment. Approximately 125 sites in North America will be recruited. Patients who report GIS during the 3 month treatment period will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented non-valvular atrial fibrillation (NVAF) for whom Pradaxa® (dabigatran etexilate) is indicated per the current local label, but who have not received treatment with Pradaxa® (dabigatran etexilate), or who have not been started on Pradaxa® (dabigatran etexilate) more than 7 days prior to potential enrolment in the study. NVAF may be documented by 12-lead , rhythm strip, pacemaker/ implantable cardioverter defibrillator (ICD) electrograms or Holter monitoring
  2. Male and female patients, age greater than or equal to 18 years at entry
  3. Written,

Exclusion criteria

Exclusion criteria:

  1. History within 2 weeks of any of the following gastrointestinal (GI) disorders: heartburn, indigestion, gastritis, upper abdominal pain or discomfort, or gastroesophageal reflux requiring the use of proton pump inhibitors, histamine-2 receptor blockers or antacids. Patients with nausea and/or vomiting within the 2 weeks are not excluded if the symptoms were clearly associated with a self-limited acute or febrile illness. Short-term use of PPIs, as prophylaxis, in a hospital setting for the prevention of stress ulcers is acceptable. Calcium carbonate supplements for calcium replacement is not exclusionary (as long as these products are being used as calcium supplementation/replacement and are not being used to treat or relieve GIS.)
  2. GI bleeding within one year or any history of symptomatic or endoscopically documented gastroduodenal ulcer or diverticulitis, unless the cause has been permanently eliminated by medical therapy or by surgery(e.g., patients with peptic ulcer disease with endoscopically proven cure after therapy or lower GI bleeding due to diverticulosis cured by segmental colectomy are not excluded.)
  3. not applicable
  4. to pantoprazole or other proton pump inhibitors, e.g. omeprazole, lansoprazole, rabeprazole, atnoprazole, esomeprazole
  5. Contraindication to Pradaxa® (dabigatran etexilate) or known to Pradaxa® (dabigatran etexilate) or its
  6. Hemorrhagic disorder, bleeding diathesis or active pathological bleeding
  7. Need for anticoagulant treatment for disorders other than atrial fibrillation
  8. Current treatment with rifampin
  9. \<15ml/min (in Canada, \<30ml/min), or patients on renal replacement therapy (dialysis)
  10. Pre-menopausal women (last menstruation less than or equal to 1 year prior to ) who: are nursing or pregnant, or are of child bearing potential and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study. Acceptable methods of birth control include abstinence, tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral implantable or injectable contraceptives, double barrier method and vasectomized partner.
  11. Patients who have received an drug in the past 30 days or are participating in another drug study
  12. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study
  13. Any condition the investigator believes would not allow safe participation in the study
  14. Contraindication in patients with mechanical heart valves. The use of Pradaxa in the setting of other forms of valvular heart disease, including the presence of a bio-prosthetic valve, is not recommended.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,067 participants (actual)

Study arms

  • Other
    Pradaxa (dabigaran etexilate)

    Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.

    Drug: Pradaxa (dabigatran etexilate)

  • Active comparator
    Pradaxa and pantoprazole

    Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal

    Drug: pantoprazole · Drug: Pradaxa (dabigatran etexilate)

  • Active comparator
    Pradaxa, 30 minutes after a meal

    Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal

    Drug: Pradaxa, within 30 minutes after a meal

Interventions

06

What researchers measure

Primary outcomes

  1. The Rate of Complete Effectiveness of Initial GIS Management Strategy

    The percentage of patients experiencing complete relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.

    Time frame: Week 4

Secondary outcomes

  1. Rate of Partial Effectiveness of Initial GIS Management Strategies

    The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) and patients taking Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

    Time frame: Week 4

  2. Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies

    The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

    Time frame: Week 4

  3. Rate of Complete Effectiveness of Combined GIS Management Strategies

    The percentage of patients experiencing complete relief of combined gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.

    Time frame: Week 8

  4. Rate of Partial Effectiveness of Combined GIS Management Strategies

    The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

    Time frame: Week 8

  5. Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies

    The percentage of patients experiencing combined of complete or partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

    Time frame: Week 8

  6. Rates of Complete Effectiveness of GIS at Each Visit.

    The percentage of patients experiencing complete effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8

  7. Rates of Partial Effectiveness of GIS at Each Visit.

    The percentage of patients experiencing partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8

  8. Rates of Complete or Partial Effectiveness of GIS at Each Visit.

    The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8

  9. Time Between Symptom Onset and First Observed Complete or Partial Effectiveness and Between Symptom Onset and Last Observed Symptom

    Time between symptom onset and first observed complete or partial effectiveness and between symptom onset and last observed symptom by management strategy.

    Time frame: Week 8

07

Results

Posted Oct 5, 2015
Limitations and caveats
The modest sample size,non-specific nature of symptoms,\&reliance on patient self-reporting of their symptoms may contributed some bias to the final result.An open-label design may lead to patient/investigator bias in reporting symptoms.

Participant flow

Not Randomized to Management Strategies
Participant flow — Not Randomized to Management Strategies
MilestonePradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never Randomized
Started00950
Without experiencing gis00854
Reported gis prior to eot visit0048
Reported gis only at eot visit0048
Completed00816
Not completed00134
Withdrew: Worsening of events associate with nvaf.001
Withdrew: Worsening of other pre-existing disease009
Withdrew: Other adverse event0054
Withdrew: Protocol violation001
Withdrew: Lost to follow-up004
Withdrew: Withdrawal by subject0010
Withdrew: Early termination0034
Withdrew: Other than stated above0021
Randomized to Management Strategies
Participant flow — Randomized to Management Strategies
MilestonePradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never Randomized
Started59580
Completed44470
Not completed15110
Withdrew: Worsening of events associate with gis320
Withdrew: Other adverse event850
Withdrew: Protocol violation300
Withdrew: Withdrawal by subject010
Withdrew: Other than stated above130
Adding the Second Strategy
Participant flow — Adding the Second Strategy
MilestonePradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never Randomized
Started14150
Completed12110
Not completed240
Withdrew: Worsening of events associate with gis110
Withdrew: Other adverse event120
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryThe Rate of Complete Effectiveness of Initial GIS Management Strategy

The percentage of patients experiencing complete relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.

Time frame:
Week 4
Reported as:
Number · percentage of participants
The Rate of Complete Effectiveness of Initial GIS Management Strategy
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
The Rate of Complete Effectiveness of Initial GIS Management Strategy55.967.2
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Fisher Exact · p = 0.2554 · Mean difference (final values): 11.31 · 95% CI -6.54 to 29.49Exact 95% Confidence interval (CI) and the difference between the two strategies were calculated using the Clopper Pearson approach.
SecondaryRate of Partial Effectiveness of Initial GIS Management Strategies

The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) and patients taking Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Rate of Partial Effectiveness of Initial GIS Management Strategies
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Rate of Partial Effectiveness of Initial GIS Management Strategies11.919.0
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Fisher Exact · p = 0.3165 · Mean difference (final values): 7.10 · 95% CI -11.24 to 24.58Exact 95% Confidence interval (CI) and the difference between the two strategies were calculated using the Clopper Pearson approach.
SecondaryCombined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies

The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies67.886.2
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Fisher Exact · p = 0.0273 · Mean difference (final values): 18.41 · 95% CI 0.71 to 35.98Exact 95% Confidence interval (CI) and the difference between the two strategies were calculated using the Clopper Pearson approach.
SecondaryRate of Complete Effectiveness of Combined GIS Management Strategies

The percentage of patients experiencing complete relief of combined gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Rate of Complete Effectiveness of Combined GIS Management Strategies
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Rate of Complete Effectiveness of Combined GIS Management Strategies42.933.3
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Fisher Exact · p = 0.7104 · Mean difference (final values): -9.52 · 95% CI -44.22 to 28.40Exact 95% Confidence interval (CI) and the difference between the two strategies were calculated using the Clopper Pearson approach.
SecondaryRate of Partial Effectiveness of Combined GIS Management Strategies

The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Rate of Partial Effectiveness of Combined GIS Management Strategies
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Rate of Partial Effectiveness of Combined GIS Management Strategies42.946.7
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Fisher Exact · p = 1.0000 · Mean difference (final values): 3.81 · 95% CI -32.94 to 40.44Exact 95% Confidence interval (CI) and the difference between the two strategies were calculated using the Clopper Pearson approach.
SecondaryCombined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies

The percentage of patients experiencing combined of complete or partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies85.780.0
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Fisher Exact · p = 1.0000 · Mean difference (final values): -5.71 · 95% CI -41.25 to 28.77Exact 95% Confidence interval (CI) and the difference between the two strategies were calculated using the Clopper Pearson approach.
SecondaryRates of Complete Effectiveness of GIS at Each Visit.

The percentage of patients experiencing complete effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8
Reported as:
Number · percentage of participants
Rates of Complete Effectiveness of GIS at Each Visit.
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Baseline (n= 59 , 58)0.00.0
GIS 3 (Week 1, n= 59 , 58)39.051.7
GIS 4 (Week 2, n= 59 , 58)45.855.2
GIS 5 (Week 3, n= 59 , 58)55.960.3
GIS 6 (Week 4, n= 59 , 58)55.967.2
GIS 7 (Week 5, n= 14 , 15)28.640.0
GIS 8 (Week 6, n= 14 , 15)42.940.0
GIS 9 (Week 7, n= 14 , 15)42.933.3
GIS 10 (Week 8, n= 14 , 15)42.933.3
SecondaryRates of Partial Effectiveness of GIS at Each Visit.

The percentage of patients experiencing partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8
Reported as:
Number · percentage of participants
Rates of Partial Effectiveness of GIS at Each Visit.
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Baseline (n= 59 , 58)0.00.0
GIS 3 (Week 1, n= 59 , 58)16.913.8
GIS 4 (Week 2, n= 59 , 58)13.624.1
GIS 5 (Week 3, n= 59 , 58)8.522.4
GIS 6 (Week 4, n= 59 , 58)11.919.0
GIS 7 (Week 5, n= 14 , 15)21.440.0
GIS 8 (Week 6, n= 14 , 15)42.940.0
GIS 9 (Week 7, n= 14 , 15)42.946.7
GIS 10 (Week 8, n= 14 , 15)42.946.7
SecondaryRates of Complete or Partial Effectiveness of GIS at Each Visit.

The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8
Reported as:
Number · percentage of participants
Rates of Complete or Partial Effectiveness of GIS at Each Visit.
percentage of participantsPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Baseline (n= 59 , 58)0.00.0
GIS 3 (Week 1, n= 59 , 58)55.965.5
GIS 4 (Week 2, n= 59 , 58)59.379.3
GIS 5 (Week 3, n= 59 , 58)64.482.8
GIS 6 (Week 4, n= 59 , 58)67.886.2
GIS 7 (Week 5, n= 14 , 15)50.080.0
GIS 8 (Week 6, n= 14 , 15)85.780.0
GIS 9 (Week 7, n= 14 , 15)85.780.0
GIS 10 (Week 8, n= 14 , 15)85.780.0
SecondaryTime Between Symptom Onset and First Observed Complete or Partial Effectiveness and Between Symptom Onset and Last Observed Symptom

Time between symptom onset and first observed complete or partial effectiveness and between symptom onset and last observed symptom by management strategy.

Time frame:
Week 8
Reported as:
Mean · days
Time Between Symptom Onset and First Observed Complete or Partial Effectiveness and Between Symptom Onset and Last Observed Symptom
daysPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)
Duration of GIS (N= 58; 58)23.5 ± 25.6723.9 ± 25.35
Time to first complete effectiveness (N= 43; 50)12.1 ± 13.4510.7 ± 10.23
Time to first partial effectiveness(N= 6; 2)23.7 ± 15.503.5 ± 2.12
Statistical analysis
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Mean difference (final values): -0.5 · 95% CI -9.9 to 8.9Mean difference = (Mean number of days for Pradaxa w/meal) - (Mean number of days for pantoprazole).
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Mean difference (final values): 1.4 · 95% CI -3.5 to 6.3Mean difference = (Mean number of days for Pradaxa w/meal) - (Mean number of days for pantoprazole).
  • Pradaxa, 30 Minutes After a Meal (Randomized) vs Pantoprazole 40 mg (Randomized) · Mean difference (final values): 20.2 · 95% CI -8.2 to 48.5Mean difference = (Mean number of days for Pradaxa w/meal) - (Mean number of days for pantoprazole).

Adverse events

Collected over From first drug administration until 6 days after end of trial, up to 158 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pradaxa, 30 Minutes After a Meal (Randomized)—2/59 (3.4%)37/59 (62.7%)
Pantoprazole 40 mg (Randomized)—3/58 (5.2%)35/58 (60.3%)
Pradaxa, Never Randomized—109/950 (11.5%)161/950 (16.9%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never Randomized
Atrial fibrillationCardiac disorders1/592/5822/950
Cardiac failure congestiveCardiac disorders0/591/5821/950
Small intestinal obstructionGastrointestinal disorders0/591/580/950
Cardiac arrestCardiac disorders1/590/582/950
Chest painGeneral disorders0/590/585/950
PneumoniaInfections and infestations0/590/585/950
Renal failure acuteRenal and urinary disorders0/590/585/950
Atrial flutterCardiac disorders0/590/584/950
Sick sinus syndromeCardiac disorders0/590/584/950
Coronary artery diseaseCardiac disorders0/590/583/950
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never Randomized
DyspepsiaGastrointestinal disorders17/5915/5873/950
Abdominal discomfortGastrointestinal disorders7/5913/5825/950
EructationGastrointestinal disorders13/5910/5825/950
Abdominal distensionGastrointestinal disorders8/5912/5823/950
Abdominal pain upperGastrointestinal disorders8/5910/5826/950
Epigastric discomfortGastrointestinal disorders9/5910/5818/950
NauseaGastrointestinal disorders5/5910/5831/950
RegurgitationGastrointestinal disorders9/594/5815/950
DiarrhoeaGastrointestinal disorders7/597/5830/950
FlatulenceGastrointestinal disorders5/595/5814/950

Baseline characteristics

Entered Set (ES): This patient set included all patients entered in the study. For those patients who were randomized to management strategies, their data prior to randomization was included in the entered set. All data from patients who were never randomized are in the entered set.

Age, Continuous
Age, Continuous(Years)Pradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never RandomizedTotal
Mean69.1 ± 11.169.6 ± 10.869.7 ± 10.769.7 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Pradaxa, 30 Minutes After a Meal (Randomized)Pantoprazole 40 mg (Randomized)Pradaxa, Never RandomizedTotal
Female2220304346
Male3738646721
08

Study locations

103 sites
  • 1160.128.1046 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 1160.128.1045 Boehringer Ingelheim Investigational Site
    Huntsville, Alabama, United States
  • 1160.128.1003 Boehringer Ingelheim Investigational Site
    Mobile, Alabama, United States
  • 1160.128.1093 Boehringer Ingelheim Investigational Site
    Chandler, Arizona, United States
  • 1160.128.1067 Boehringer Ingelheim Investigational Site
    Hot Springs, Arkansas, United States
  • 1160.128.1103 Boehringer Ingelheim Investigational Site
    Mesa, California, United States
  • 1160.128.1094 Boehringer Ingelheim Investigational Site
    Newport Beach, California, United States
  • 1160.128.1042 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1160.128.1005 Boehringer Ingelheim Investigational Site
    Colorado Spring, Colorado, United States
  • 1160.128.1023 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 1160.128.1016 Boehringer Ingelheim Investigational Site
    Bridgeport, Connecticut, United States
  • 1160.128.1066 Boehringer Ingelheim Investigational Site
    Bridgeport, Connecticut, United States
  • 1160.128.1018 Boehringer Ingelheim Investigational Site
    Guilford, Connecticut, United States
  • 1160.128.1050 Boehringer Ingelheim Investigational Site
    Norwalk, Connecticut, United States
  • 1160.128.1057 Boehringer Ingelheim Investigational Site
    Waterbury, Connecticut, United States
  • 1160.128.1085 Boehringer Ingelheim Investigational Site
    Washington, District of Columbia, United States
  • 1160.128.1111 Boehringer Ingelheim Investigational Site
    Atlantis, Florida, United States
  • 1160.128.1032 Boehringer Ingelheim Investigational Site
    Brandon, Florida, United States
  • 1160.128.1021 Boehringer Ingelheim Investigational Site
    Coral Springs, Florida, United States
  • 1160.128.1027 Boehringer Ingelheim Investigational Site
    Daytona Beach, Florida, United States
  • 1160.128.1019 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.128.1062 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.128.1054 Boehringer Ingelheim Investigational Site
    Largo, Florida, United States
  • 1160.128.1097 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1160.128.1109 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1160.128.1087 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 1160.128.1058 Boehringer Ingelheim Investigational Site
    Pensacola, Florida, United States
  • 1160.128.1007 Boehringer Ingelheim Investigational Site
    Port Charlotte, Florida, United States
  • 1160.128.1060 Boehringer Ingelheim Investigational Site
    Rockledge, Florida, United States
  • 1160.128.1096 Boehringer Ingelheim Investigational Site
    Columbus, Georgia, United States
  • 1160.128.1068 Boehringer Ingelheim Investigational Site
    Roswell, Georgia, United States
  • 1160.128.1076 Boehringer Ingelheim Investigational Site
    Coeur d' Alene, Idaho, United States
  • 1160.128.1073 Boehringer Ingelheim Investigational Site
    Melrose Park, Illinois, United States
  • 1160.128.1048 Boehringer Ingelheim Investigational Site
    Winfield, Illinois, United States
  • 1160.128.1105 Boehringer Ingelheim Investigational Site
    Hammond, Indiana, United States
  • 1160.128.1029 Boehringer Ingelheim Investigational Site
    Indianapolis, Indiana, United States
  • 1160.128.1079 Boehringer Ingelheim Investigational Site
    Overland Park, Kansas, United States
  • 1160.128.1008 Boehringer Ingelheim Investigational Site
    Baton Rouge, Louisiana, United States
  • 1160.128.1025 Boehringer Ingelheim Investigational Site
    Auburn, Maine, United States
  • 1160.128.1100 Boehringer Ingelheim Investigational Site
    Biddeford, Maine, United States
  • 1160.128.1041 Boehringer Ingelheim Investigational Site
    Columbia, Maryland, United States
  • 1160.128.1012 Boehringer Ingelheim Investigational Site
    Salisbury, Maryland, United States
  • 1160.128.1015 Boehringer Ingelheim Investigational Site
    Rochester Hills, Michigan, United States
  • 1160.128.1004 Boehringer Ingelheim Investigational Site
    Tupelo, Mississippi, United States
  • 1160.128.1014 Boehringer Ingelheim Investigational Site
    Columbia, Missouri, United States
  • 1160.128.1047 Boehringer Ingelheim Investigational Site
    Kansas City, Missouri, United States
  • 1160.128.1075 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 1160.128.1069 Boehringer Ingelheim Investigational Site
    Great Falls, Montana, United States
  • 1160.128.1011 Boehringer Ingelheim Investigational Site
    Kalispell, Montana, United States
  • 1160.128.1092 Boehringer Ingelheim Investigational Site
    Lincoln, Nebraska, United States
  • 1160.128.1059 Boehringer Ingelheim Investigational Site
    Omaha, Nebraska, United States
  • 1160.128.1039 Boehringer Ingelheim Investigational Site
    Elmer, New Jersey, United States
  • 1160.128.1035 Boehringer Ingelheim Investigational Site
    Flemington, New Jersey, United States
  • 1160.128.1036 Boehringer Ingelheim Investigational Site
    Albuquerque, New Mexico, United States
  • 1160.128.1063 Boehringer Ingelheim Investigational Site
    Hawthorne, New York, United States
  • 1160.128.1078 Boehringer Ingelheim Investigational Site
    Mineola, New York, United States
  • 1160.128.1001 Boehringer Ingelheim Investigational Site
    Poughkeepsie, New York, United States
  • 1160.128.1022 Boehringer Ingelheim Investigational Site
    Asheville, North Carolina, United States
  • 1160.128.1052 Boehringer Ingelheim Investigational Site
    Gastonia, North Carolina, United States
  • 1160.128.1071 Boehringer Ingelheim Investigational Site
    Statesville, North Carolina, United States
  • 1160.128.1091 Boehringer Ingelheim Investigational Site
    Gallipolis, Ohio, United States
  • 1160.128.1107 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 1160.128.1053 Boehringer Ingelheim Investigational Site
    Bend, Oregon, United States
  • 1160.128.1033 Boehringer Ingelheim Investigational Site
    Hillsboro, Oregon, United States
  • 1160.128.1037 Boehringer Ingelheim Investigational Site
    Altoona, Pennsylvania, United States
  • 1160.128.1034 Boehringer Ingelheim Investigational Site
    Camp Hill, Pennsylvania, United States
  • 1160.128.1010 Boehringer Ingelheim Investigational Site
    Langhorne, Pennsylvania, United States
  • 1160.128.1056 Boehringer Ingelheim Investigational Site
    Pittsburgh, Pennsylvania, United States
  • 1160.128.1065 Boehringer Ingelheim Investigational Site
    Uniontown, Pennsylvania, United States
  • 1160.128.1043 Boehringer Ingelheim Investigational Site
    Charleston, South Carolina, United States
  • 1160.128.1040 Boehringer Ingelheim Investigational Site
    Rapid City, South Dakota, United States
  • 1160.128.1006 Boehringer Ingelheim Investigational Site
    Austin, Texas, United States
  • 1160.128.1104 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1160.128.1061 Boehringer Ingelheim Investigational Site
    McKinney, Texas, United States
  • 1160.128.1090 Boehringer Ingelheim Investigational Site
    New Braunfels, Texas, United States
  • 1160.128.1082 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 1160.128.1102 Boehringer Ingelheim Investigational Site
    Layton, Utah, United States
  • 1160.128.1077 Boehringer Ingelheim Investigational Site
    Danville, Virginia, United States
  • 1160.128.1064 Boehringer Ingelheim Investigational Site
    Falls Church, Virginia, United States
  • 1160.128.1110 Boehringer Ingelheim Investigational Site
    Manassas, Virginia, United States
  • 1160.128.1099 Boehringer Ingelheim Investigational Site
    Norfolk, Virginia, United States
  • 1160.128.1160 Boehringer Ingelheim Investigational Site
    Calgary, Alberta, Canada
  • 1160.128.1159 Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • 1160.128.1152 Boehringer Ingelheim Investigational Site
    Red Deer, Alberta, Canada
  • 1160.128.1153 Boehringer Ingelheim Investigational Site
    Spruce Grove, Alberta, Canada
  • 1160.128.1167 Boehringer Ingelheim Investigational Site
    Coquitlam, British Columbia, Canada
  • 1160.128.1158 Boehringer Ingelheim Investigational Site
    Victoria, British Columbia, Canada
  • 1160.128.1154 Boehringer Ingelheim Investigational Site
    Saint John, New Brunswick, Canada
  • 1160.128.1166 Boehringer Ingelheim Investigational Site
    Bay Roberts, Newfoundland and Labrador, Canada
  • 1160.128.1151 Boehringer Ingelheim Investigational Site
    Brampton, Ontario, Canada
  • 1160.128.1168 Boehringer Ingelheim Investigational Site
    Cambridge, Ontario, Canada
  • 1160.128.1164 Boehringer Ingelheim Investigational Site
    Collingwood, Ontario, Canada
  • 1160.128.1173 Boehringer Ingelheim Investigational Site
    Corunna, Ontario, Canada
  • 1160.128.1156 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1160.128.1157 Boehringer Ingelheim Investigational Site
    Kitchener, Ontario, Canada
  • 1160.128.1155 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1160.128.1170 Boehringer Ingelheim Investigational Site
    Peterborough, Ontario, Canada
  • 1160.128.1165 Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • 1160.128.1169 Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • 1160.128.1161 Boehringer Ingelheim Investigational Site
    Stayner, Ontario, Canada

Showing the first 100 of 103 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • O'Dea D, Whetteckey J, Ting N. A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran. Cardiol Ther. 2016 Dec;5(2):187-201. doi: 10.1007/s40119-016-0071-5. Epub 2016 Oct 5. PubMed 27709460 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2011
First posted
Dec 16, 2011
Start
Dec 2011
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Oct 5, 2015
Last update
Oct 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01493557
Responsible party
Sponsor
First posted
Dec 16, 2011
Start date
Dec 2011
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Oct 5, 2015
Last update
Oct 5, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pantoprazole · Dabigatran

Start the discussion